Results 51 to 60 of about 1,013 (109)

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

New-Onset Autoantibody-Negative Diabetes With DKA Following Lorlatinib Therapy for ALK-Positive NSCLC

Case Reports in Endocrinology
Lorlatinib, a tyrosine kinase inhibitor used in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), is associated with adverse events, including hyperglycemia.
Ashni Dharia, Anna Pleet, Brittany West, Gayatri Jaiswal   +3 more
doaj   +1 more source

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC

Thoracic Cancer, 2023
Background To dynamically monitor the changes of genomic characteristics during lorlatinib treatment and analyze the resistance profile of lorlatinib in ALK‐positive advanced Chinese patients with non‐small cell lung cancer (NSCLC) with first‐ and second‐
Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu   +8 more
doaj   +1 more source

First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review

Respirology Case Reports, Volume 14, Issue 9, September 2026.
A 45‐year‐old male with STRN–ALK‐positive lung adenocarcinoma and brain metastases achieved a significant and durable response to first‐line lorlatinib. Together with our literature review of 15 previously reported cases, this case supports further evaluation of lorlatinib as a first‐line treatment option for patients harbouring this rare ALK fusion ...
Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta   +4 more
wiley   +1 more source

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Nature Communications, 2021
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung ...
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +23 more
doaj   +1 more source

Radioiodine‐Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy

Cancer Innovation, Volume 5, Issue 4, August 2026.
Radioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Yamin Li, Zuoxiang He
wiley   +1 more source

Investigation of the Mechanism of Lorlatinib-Induced Hepatotoxicity: Reactive Metabolites of Lorlatinib Activate Inflammasomes

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, is widely used to treat ALK-positive nonsmall cell lung cancer. However, lorlatinib has occasionally been associated with severe liver injury.
Haruna Takagaki, Jina Suzuki, Serina Mizuguchi, Mayuko Tamura-Takaori, Chihiro Otsubo, Ryuji Kato, Takumi Noda, Ayumi Fujimoto, Saori Tanaka, Kazuya Urashima, Ayaka Kidani, Yuka Kohda   +11 more
core   +1 more source

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib

, 2021
The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients.
Jean C. Grégoire, Normand Blais, Jean-Philippe Adam, John Nguyen   +3 more
core   +1 more source

Up to Four‐Year Outcomes of Single‐Fraction Stereotactic Radiosurgery for Small Brain Metastases: A Competing‐Risk Analysis

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Introduction Single‐fraction stereotactic radiosurgery (SRS) is recommended for small brain metastases (< 2 cm). However, long‐term outcomes accounting for competing risks—particularly death, which precludes observation of local treatment failure (LTF)—remain limited. Methods We retrospectively analyzed cumulative incidences of LTF, defined as
Isabella Gruber, Oliver Koelbl
wiley   +1 more source

Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

, 2023
The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor, has demonstrated significant systemic and intracranial activity in ...
Dursun, Oldac U., Mehmet AN Sendur, Demirci, Umut, Saadettin Kilickap, Nuri Karadurmus, ŞENDUR, MEHMET ALİ NAHİT, Sendur, Mehmet A. N., Umut Demirci, Sertac Ak, Oldac U Dursun, AK, SERTAÇ, Karadurmus, Nuri, Kilickap, Saadettin   +12 more
core   +1 more source